(Q46957709)

English

Two weeks' quetiapine treatment for schizophrenia, drug-induced psychosis and borderline personality disorder: a naturalistic study with drug plasma levels

scientific article published in October 2007

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17927477

Two weeks' quetiapine treatment for schizophrenia, drug-induced psychosis and borderline personality disorder: a naturalistic study with drug plasma levels (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17927477

borderline personality disorder

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Massimo C Mauri

1

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17927477

Lucia S Volonteri

2

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17927477

Alessio Fiorentini

3

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17927477

Rodolfo Pirola

4

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17927477

Silvio R Bareggi

5

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17927477

language of work or name

0 references

publication date

1 October 2007

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17927477

Expert Opinion on Pharmacotherapy

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17927477

8

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17927477

14

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17927477

2207-2213

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17927477

D(2) and 5HT(2A) receptor occupancy of different doses of quetiapine in schizophrenia: a PET study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2207

21 January 2018

Clinical pharmacokinetics of quetiapine: an atypical antipsychotic

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2207

21 January 2018

Quetiapine : A Review of its Use in Schizophrenia

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2207

21 January 2018

A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2207

21 January 2018

The efficacy of quetiapine vs haloperidol and placebo: a meta-analytic study of efficacy

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2207

21 January 2018

Efficacy of newer generation antipsychotics in the treatment of schizophrenia

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2207

21 January 2018

A post hoc analysis of the impact on hostility and agitation of quetiapine and haloperidol among patients with schizophrenia

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2207

21 January 2018

Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2207

21 January 2018

Quetiapine for the treatment of borderline personality disorder; an open-label study

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2207

21 January 2018

Safety and efficacy of risperidone in substance abusers with psychosis

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2207

21 January 2018

Potential use of olanzapine in treatment of substance dependence disorders

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2207

21 January 2018

Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2207

21 January 2018

ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2207

21 January 2018

HPLC analysis of the novel antipsychotic drug quetiapine in human plasma

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2207

21 January 2018

Quetiapine. A review of its use in the management of schizophrenia

1 reference

https://api.crossref.org/works/10.1517%2F14656566.8.14.2207

21 January 2018

Identifiers

10.1517/14656566.8.14.2207

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17927477

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 December 2017

http://europepmc.org/abstract/MED/17927477

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46957709&oldid=2139688956"